In vivo efficacy of drugs against Toxoplasma gondii combined with Immunomodulators

Japanese Journal of Infectious Diseases

Volumn 69, Issue 2, 2016, Pages 113-117

  Köksal, Zeynep Şentürk ^a   Yanik, Keramettin ^b   Bilgin, Kemal ^b   Yılmaz, Esmeray Mutlu ^c   Hokelek, Murat ^d  

^a Gazi State Hospital Samsun   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c SAMSUN TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINACEA EXTRACT; IMMUNOMODULATING AGENT; LEVAMISOLE; PYRIMETHAMINE; SULFADIAZINE; ANTIPROTOZOAL AGENT; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; SURVIVAL RATE; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PROCEDURES; SURVIVAL ANALYSIS; TOXOPLASMA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOLOGIC FACTORS; LEVAMISOLE; MICE, INBRED BALB C; PYRIMETHAMINE; SULFADIAZINE; SURVIVAL ANALYSIS; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME;

EID: 84961678088     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.JJID.2015.023     Document Type: Article

References (30)

1. Altintaş N, Kuman HA, Akisu C, et al. Toxoplasmosis in last four years in Ageon region, Turkey. J Egypt Soc Parsitol. 1997; 27:439-43
2. Gürüz AY, Özcel MA. Toxoplasmosis. In: Özcel MA, editor. Medical Parasitic Diseases. Izmir, Turkey: Turkish Society for Parasitology Press; 2007. p. 141-189. Turkish.
3. Rosenthal PJ, Goldsmith RS. Protozoal and helminthic infections. In: Trierney LM, Papadakis MA, McPhee SJ, editors. Current Medical Diagnosis & Treatment. Lange Medical Books, 40th edition. New York, NY: McGraw-Hill Education; 2001. p. 1444-1447
4. Ajioka, JW, Soldati D. Preface. In: Ajioka JW, Soldati D, editors. Toxoplasma. Molecular and Cellular Biology. Norfolk, VA: Horizon Bioscience Scientific Press; 2007. p. 3-8
5. Töre O. Toxoplasmosis. In: Topçu AW, Soyletir G, Doganay M, editors. Infectious Diseases. Istanbul, Turkey: Nobel Tıp Kitabevleri; 1996. p. 525-532. Turkish.
6. Lebech M, Andersen O, Christensen NC, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet. 1999;353:1834-7
7. Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med. 2007;12: 214-23
8. Araujo FG, Khan AA, Remington JS. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob Agents Chemother. 1996;40:1335-7
9. Montoya JG, Remington JS. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Philadelphia, PA: Elsevier; 2008. p. 2858-2888
10. Pfefferkorn ER, Borotz SE. Comparison of mutants of Toxoplasma gondii selected for resistant to azithromycin, spiramycin, or clindamycin. Antimicrob Agents Chemother. 1994;38:31-7
11. Reynolds MG, Oh J, Roos DS. In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother. 2001;45: 1271-7
12. Bauer VR, Jurcic K, Puhlmann J, et al. Immunologic in vivo and in vitro studies on Echinacea extracts. Arzneimittelforschung. 1988;38:276-81
13. Luettig B, Steinmuller C, Gifford GE, et al. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. J Natl Cancer Inst. 1989;81: 669-75
14. Stevenson LM, Matthias A, Banbury L, et al. Modulation of macrophage immune responses by Echinacea. Molecules. 2005; 10:1279-85
15. Sullivan AM, Laba JG, Moore JA, et al. Echinacea-induced macrophage activation. Immunopharmacol Immunotoxicol. 2008;30: 553-74
16. Zhai Z, Liu Y, Wu L, et al. Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food. 2007;10:423-34
17. Rişvanlı A, Aydın M. The effects of levamisole on the pregnancy rate, avarage litter size, sexuality, living rate and lactation period in rats. Fırat University Medical Journal of Health. 2003;17:45-7. Turkish.
18. Brunner CJ, Muscoplat CC. Immunomodulatory effects of levamisole. J Am Vet Med Assoc. 1980;176:1159-62
19. Kimball ES, Clark MC, Schneider CR, et al. Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole. Clin Immunol Immunopathol. 1991;58:385-98
20. İspir Ü, Dörücü MA. Study on the effects of levamisole on the immune system of rainbow trout (Oncorhynchus mykiss, Walbaum). Turk J Vet Anim. 2005;29:1169-76
21. Khan AA, Slifer T, Araujo FG, et al. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Antimicrob Agents Chemother. 1997;41:893-7
22. Khan AA, Slifer TR, Araujo FG, et al. Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother. 2001;45:48-51
23. Romand S, Bryskier A, Moutot M, et al. In vitro and in vivo activities of roxithromycin in combination with pyrimethamine or sulfadiazine against Toxoplasma gondii. J Antimicrob Chemother. 1995;35:821-32
24. Araujo FG, Prokocimer P, Lin T, et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother. 1992;36: 2454-7
25. Derouin F, Almadany R, Chau F, et al. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob Agents Chemother. 1992; 36:997-1001
26. Romand S, Pudney M, Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother. 1993;37:2371-8
27. Ferreira RA, Oliveira AB, Ribeiro MF, et al. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1?-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. Exp Parasitol. 2006;113:125-9
28. Khan AA, Nasr M, Araujo FG. Two 2-hydroxy-3-alkyl-1,4- naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii. Antimicrob Agents Chemother. 1998;42:2284-9
29. Berkner D, Sioris L. Echinacea herbal products. In: Tracey TS, Kingston RL, editors. Herbal Products: Toxicology and Clinical Pharmacology of Herbal Products. Totowa, NJ: Humana Press; 2007. p.97-109
30. Kayaalp O. Antiamoebic drugs and other antiprotozoal drugs. In: Kayaalp O, editor. Rational Treatment Aspect of Medical Pharmacology. 12th edition. Ankara, Turkey. Pelikan Press; 2009. p. 344-354. Turkish.